Back to Dermatology
Dermatologyv2001Evidence-Based

Eczema Area and Severity Index (EASI)

Stratifies eczema severity by assessing area involvement and severity signs across four body regions (head/neck, upper extremities, trunk, lower extremities) with validated clinical scoring.

Clinical Input Parameters

Range: 0 — 6
Range: 0 — 3
Range: 0 — 3
Range: 0 — 3
Range: 0 — 3
Range: 0 — 6
Range: 0 — 3
Range: 0 — 3
Range: 0 — 3
Range: 0 — 3
Range: 0 — 6
Range: 0 — 3
Range: 0 — 3
Range: 0 — 3
Range: 0 — 3
Range: 0 — 6
Range: 0 — 3
Range: 0 — 3
Range: 0 — 3
Range: 0 — 3
Clinical Assessment
Awaiting Parameters
easi score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Eczema Area and Severity Index (EASI) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within dermatology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

EASI = 0.1 × (erythema + edema + excoriation + lichenification) × area_score × head_neck_multiplier + 0.2 × (erythema + edema + excoriation + lichenification) × area_score × upper_extremities_multiplier + 0.3 × (erythema + edema + excoriation + lichenification) × area_score × trunk_multiplier + 0.4 × (erythema + edema + excoriation + lichenification) × area_score × lower_extremities_multiplier. Regional multipliers: Head/neck = 0.1 (adults), 0.2 (children 0-7); Upper extremities = 0.2; Trunk = 0.3; Lower extremities = 0.4.

Clinical Pearls & Practice Notes

  • The EASI is the most validated and widely used assessment tool for atopic dermatitis severity.
  • Assessment requires approximately 6 minutes when performed by a trained investigator.
  • Area involvement: 0=0%, 1=1-9%, 2=10-29%, 3=30-49%, 4=50-69%, 5=70-89%, 6=90-100%
  • Severity signs rated 0-3: 0=absent, 1=mild, 2=moderate, 3=severe
  • Four severity signs assessed: erythema (redness), edema/papulation (swelling/bumps), excoriation (scratching marks), lichenification (thickening)
  • Regional multipliers reflect relative contribution to total body surface area.
  • Head/neck multiplier: 0.1 for adults (>8 years), 0.2 for children (0-7 years)
  • Upper extremities multiplier: 0.2 for all ages
  • Trunk multiplier: 0.3 for all ages (includes axilla and groin)
  • Lower extremities multiplier: 0.4 for all ages (includes feet and buttocks)
  • Total score ranges from 0 to 72 points.
  • Common pitfall: underestimating erythema severity in patients with darker skin pigmentation.
  • EASI should be completed independently of previous assessments - it is a static tool.
  • Does not include assessment of dryness or scaling.
  • Severity strata validated with substantial inter-rater agreement (κ = 0.75).
  • Clinical correlation: Higher EASI scores associated with increased pruritus, sleep disturbance, and quality of life impairment.
  • Recommended for clinical trials and research as primary efficacy endpoint.

Evidence & Literature Citations

  1. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10(1):11-8. doi: 10.1034/j.1600-0625.2001.100102.x.
  2. Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132(6):1337-47. doi: 10.1016/j.jaci.2013.07.008.
  3. Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi: 10.1111/all.13401.
  4. Silverberg JI, Paller AS, Fishbein AB, Kaplan DH, Simpson EL. Eczema prevalence, severity and impact in the United States. Dermatitis. 2019;30(1):66-72. doi: 10.1097/DER.0000000000000408.

Score Interpretation Ranges

Clear0 – 0 pts

No eczema

Almost Clear0.1 – 1 pts

Almost clear eczema

Mild1.1 – 7 pts

Mild eczema

Moderate7.1 – 21 pts

Moderate eczema

Severe21.1 – 50 pts

Severe eczema

Very Severe50.1 – 72 pts

Very severe eczema

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.